Colcrys

COLCRYS- colchicine tablet, film coated
Proficient Rx LP

1 INDICATIONS AND USAGE

1.1 Gout Flares

COLCRYS (colchicine, USP) tablets are indicated for prophylaxis and the treatment of acute gout flares.

Prophylaxis of Gout Flares:
COLCRYS is indicated for prophylaxis of gout flares.
Treatment of Gout Flares: COLCRYS tablets are indicated for treatment of acute gout flares when taken at the first sign of a flare.

1.2 Familial Mediterranean Fever (FMF)

COLCRYS (colchicine, USP) tablets are indicated in adults and children 4 years or older for treatment of familial Mediterranean fever (FMF).

2 DOSAGE AND ADMINISTRATION

The long-term use of colchicine is established for FMF and the prophylaxis of gout flares, but the safety and efficacy of repeat treatment for gout flares has not been evaluated. The dosing regimens for COLCRYS are different for each indication and must be individualized.

The recommended dosage of COLCRYS depends on the patient’s age, renal function, hepatic function and use of coadministered drugs [see Dose Modification for Coadministration of Interacting Drugs (2.4) ].

COLCRYS tablets are administered orally without regard to meals.

COLCRYS is not an analgesic medication and should not be used to treat pain from other causes.

2.1 Gout Flares

Prophylaxis of Gout Flares

The recommended dosage of COLCRYS for prophylaxis of gout flares for adults and adolescents older than 16 years of age is 0.6 mg once or twice daily. The maximum recommended dose for prophylaxis of gout flares is 1.2 mg/day.

An increase in gout flares may occur after initiation of uric acid-lowering therapy, including pegloticase, febuxostat and allopurinol, due to changing serum uric acid levels resulting in mobilization of urate from tissue deposits. COLCRYS is recommended upon initiation of gout flare prophylaxis with uric acid-lowering therapy. Prophylactic therapy may be beneficial for at least the first six months of uric acid-lowering therapy.

Treatment of Gout Flares

The recommended dose of COLCRYS for treatment of a gout flare is 1.2 mg (two tablets) at the first sign of the flare followed by 0.6 mg (one tablet) one hour later. Higher doses have not been found to be more effective. The maximum recommended dose for treatment of gout flares is 1.8 mg over a one hour period. COLCRYS may be administered for treatment of a gout flare during prophylaxis at doses not to exceed 1.2 mg (two tablets) at the first sign of the flare followed by 0.6 mg (one tablet) one hour later. Wait 12 hours and then resume the prophylactic dose.

2.2 FMF

The recommended dosage of COLCRYS for FMF in adults is 1.2 mg to 2.4 mg daily.

COLCRYS should be increased as needed to control disease and as tolerated in increments of 0.3 mg/day to a maximum recommended daily dose. If intolerable side effects develop, the dose should be decreased in increments of 0.3 mg/day. The total daily COLCRYS dose may be administered in one to two divided doses.

2.3 Recommended Pediatric Dosage

Prophylaxis and Treatment of Gout Flares

COLCRYS is not recommended for pediatric use in prophylaxis or treatment of gout flares.

FMF

The recommended dosage of COLCRYS for FMF in pediatric patients 4 years of age and older is based on age. The following daily doses may be given as a single or divided dose twice daily:

Children 4 to 6 years: 0.3 mg to 1.8 mg daily
Children 6 to 12 years: 0.9 mg to 1.8 mg daily
Adolescents older than 12 years: 1.2 mg to 2.4 mg daily

2.4 Dose Modification for Coadministration of Interacting Drugs

Concomitant Therapy

Coadministration of COLCRYS with drugs known to inhibit CYP3A4 and/or P-glycoprotein (P-gp) increases the risk of colchicine-induced toxic effects (Table 1). If patients are taking or have recently completed treatment with drugs listed in Table 1 within the prior 14 days, the dose adjustments are as shown in the table below [see Drug Interactions (7) ].

Table 1 COLCRYS Dose Adjustment for Coadministration with Interacting Drugs if no Alternative Available *
*
For magnitude of effect on colchicine plasma concentrations [see Pharmacokinetics (12.3) ]
When used in combination with Ritonavir, see dosing recommendations for strong CYP3A4 inhibitors [see Contraindications (4) ]
Patients with renal or hepatic impairment should not be given COLCRYS in conjunction with strong CYP3A4 or P-gp inhibitors [see Contraindications (4) ]

Strong CYP3A4 Inhibitors 2

Drug

Noted or Anticipated Outcome

Gout Flares

FMF

Prophylaxis of Gout Flares

Treatment of Gout Flares

Original Intended Dosage

Adjusted Dose

Original Intended Dosage

Adjusted Dose

Original Intended Dosage

Adjusted Dose

AtazanavirClarithromycinDarunavir/Ritonavir IndinavirItraconazole KetoconazoleLopinavir/Ritonavir NefazodoneNelfinavirRitonavirSaquinavir TelithromycinTipranavir/Ritonavir

Significant increase in colchicine plasma levels *; fatal colchicine toxicity has been reported with clarithromycin, a strong CYP3A4 inhibitor. Similarly, significant increase in colchicine plasma levels is anticipated with other strong CYP3A4 inhibitors.

0.6 mg twice a day0.6 mg once a day

0.3 mg once a day0.3 mg once every other day

1.2 mg(2 tablets) followed by 0.6 mg (1 tablet) 1 hour later. Dose to be repeated no earlier than 3 days.

0.6 mg(1 tablet) × 1 dose, followed by 0.3 mg (1/2 tablet) 1 hour later. Dose to be repeated no earlier than 3 days.

Maximum daily dose of 1.2 – 2.4 mg

Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day)

Moderate CYP3A4 Inhibitors

Drug

Noted or Anticipated Outcome

Gout Flares

FMF

Prophylaxis of Gout Flares

Treatment of Gout Flares

Original Intended Dosage

Adjusted Dose

Original Intended Dosage

Adjusted Dose

Original Intended Dosage

Adjusted Dose

Amprenavir AprepitantDiltiazem Erythromycin Fluconazole Fosamprenavir (pro-drug ofAmprenavir)Grapefruit juiceVerapamil

Significant increase in colchicine plasma concentration is anticipated. Neuromuscular toxicity has been reported with diltiazem and verapamil interactions.

0.6 mg twice a day0.6 mg once a day

0.3 mg twice a day or 0.6 mg once a day0.3 mg once a day

1.2 mg(2 tablets) followed by 0.6 mg (1 tablet) 1 hour later. Dose to be repeated no earlier than 3 days.

1.2 mg(2 tablets) × 1 dose. Dose to be repeated no earlier than 3 days.

Maximum daily dose of 1.2 – 2.4 mg.

Maximum daily dose of 1.2 mg (may be given as 0.6 mg twice a day)

P-gp Inhibitors

Drug

Noted or Anticipated Outcome

Gout Flares

FMF

Prophylaxis of Gout Flares

Treatment of Gout Flares

Original Intended Dosage

Adjusted Dose

Original Intended Dosage

Adjusted Dose

Original Intended Dosage

Adjusted Dose

Cyclosporine Ranolazine

Significant increase in colchicine plasma levels *; fatal colchicine toxicity has been reported with cyclosporine, a P-gp inhibitor. Similarly, significant increase in colchicine plasma levels is anticipated with other P-gp inhibitors.

0.6 mg twice a day0.6 mg once a day

0.3 mg once a day0.3 mg once every other day

1.2 mg(2 tablets) followed by 0.6 mg (1 tablet) 1 hour later. Dose to be repeated no earlier than 3 days.

0.6 mg(1 tablet) × 1 dose. Dose to be repeated no earlier than 3 days.

Maximum daily dose of 1.2 – 2.4 mg

Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day)

Table 2 COLCRYS Dose Adjustment for Coadministration with Protease Inhibitors

Protease Inhibitor

Clinical Comment

w/Colchicine — Prophylaxis of Gout Flares

w/Colchicine - Treatment of Gout Flares

w/Colchicine — Treatment of FMF

Atazanavir sulfate(Reyataz)

Patients with renal or hepatic impairment should not be given colchicine with Reyataz.

Original dose

Adjusted dose

0.6 mg (1 tablet) × 1 dose, followed by 0.3 mg (1/2 tablet) 1 hour later. Dose to be repeated no earlier than 3 days.

Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day)

0.6 mg twice a day0.6 mg once a day

0.3 mg once a day0.3 mg once every other day

Darunavir (Prezista)

Patients with renal or hepatic impairment should not be given colchicine with Prezista/ritonavir.

Original dose

Adjusted dose

0.6 mg (1 tablet) × 1 dose, followed by 0.3 mg (1/2 tablet) 1 hour later. Dose to be repeated no earlier than 3 days.

Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day)

0.6 mg twice a day0.6 mg once a day

0.3 mg once a day0.3 mg once every other day

Fosamprenavir (Lexiva) with Ritonavir

Patients with renal or hepatic impairment should not be given colchicine with Lexiva/ritonavir.

Original dose

Adjusted dose

0.6 mg (1 tablet) × 1 dose, followed by 0.3 mg (1/2 tablet) 1 hour later. Dose to be repeated no earlier than 3 days.

Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day)

0.6 mg twice a day0.6 mg once a day

0.3 mg once a day0.3 mg once every other day

Fosamprenavir (Lexiva)

Patients with renal or hepatic impairment should not be given colchicine with Lexiva/ritonavir.

Original dose

Adjusted dose

1.2 mg (2 tablets) × 1 dose. Dose to be repeated no earlier than 3 days.

Maximum daily dose of 1.2 mg (may be given as 0.6 mg twice a day)

0.6 mg twice a day0.6 mg once a day

0.3 mg twice a day or 0.6 mg once a day0.3 mg once a day

Indinavir (Crixivan)

Patients with renal or hepatic impairment should not be given colchicine with Crixivan.

Original dose

Adjusted dose

0.6 mg (1 tablet) × 1 dose, followed by 0.3 mg (1/2 tablet) 1 hour later. Dose to be repeated no earlier than 3 days.

Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day)

0.6 mg twice a day0.6 mg once a day

0.3 mg once a day0.3 mg once every other day

Lopinavir/Ritonavir (Kaletra)

Patients with renal or hepatic impairment should not be given colchicine with Kaletra.

Original dose

Adjusted dose

0.6 mg (1 tablet) × 1 dose, followed by 0.3 mg (1/2 tablet) 1 hour later. Dose to be repeated no earlier than 3 days.

Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day)

0.6 mg twice a day0.6 mg once a day

0.3 mg once a day0.3 mg once every other day

Nelfinavir mesylate (Viracept)

Patients with renal or hepatic impairment should not be given colchicine with Viracept.

Original dose

Adjusted dose

0.6 mg (1 tablet) × 1 dose, followed by 0.3 mg (1/2 tablet) 1 hour later. Dose to be repeated no earlier than 3 days.

Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day)

0.6 mg twice a day0.6 mg once a day

0.3 mg once a day0.3 mg once every other day

Ritonavir (Norvir)

Patients with renal or hepatic impairment should not be given colchicine with Norvir.

Original dose

Adjusted dose

0.6 mg (1 tablet) × 1 dose, followed by 0.3 mg (1/2 tablet) 1 hour later. Dose to be repeated no earlier than 3 days.

Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day)

0.6 mg twice a day0.6 mg once a day

0.3 mg once a day0.3 mg once every other day

Saquinavir mesylate (Invirase)

Patients with renal or hepatic impairment should not be given colchicine with Invirase/ritonavir.

Original dose

Adjusted dose

0.6 mg (1 tablet) × 1 dose, followed by 0.3 mg (1/2 tablet) 1 hour later. Dose to be repeated no earlier than 3 days.

Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day)

0.6 mg twice a day0.6 mg once a day

0.3 mg once a day0.3 mg once every other day

Tipranavir (Aptivus)

Patients with renal or hepatic impairment should not be given colchicine with Aptivus/ritonavir.

Original dose

Adjusted dose

0.6 mg (1 tablet) × 1 dose, followed by 0.3 mg (1/2 tablet) 1 hour later. Dose to be repeated no earlier than 3 days.

Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day)

0.6 mg twice a day0.6 mg once a day

0.3 mg once a day0.3 mg once every other day

Treatment of gout flares with COLCRYS is not recommended in patients receiving prophylactic dose of COLCRYS and CYP3A4 inhibitors.

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2020. All Rights Reserved.